Search
Xeris Biopharma Holdings Inc
XERSAdd to Watchlist
8.200USD
+0.040+0.49%
Close 09-18 16:00（ET）
1.42BMarket Cap
106.45P/E TTM
Xeris Biopharma Holdings Inc (XERS) Revenue Performance
Updated: Jun 30, 2026By Business
Revenue
Proportion
Annual
Annual
Quarterly
Product revenue -Recorlev
Product revenue - Gvoke
Product revenue - Keveyis
Royalty, contract and other revenue
Other product revenue
Product revenue -Recorlev
FY2025
FY2024
FY2023
FY2022
Product revenue -Recorlev
139.28M(47.72%)
--(--)
--(--)
--(--)
Product revenue - Gvoke
94.11M(32.25%)
82.83M(40.79%)
67.05M(40.90%)
52.53M(47.64%)
Product revenue - Keveyis
47.65M(16.33%)
49.53M(24.39%)
56.77M(34.64%)
49.31M(44.72%)
Royalty, contract and other revenue
8.84M(3.03%)
6.43M(3.17%)
10.55M(6.44%)
985.00K(0.89%)
Other product revenue
1.96M(0.67%)
--(--)
--(--)
--(--)
Product revenue -Recorlev
--(--)
64.28M(31.65%)
29.55M(18.03%)
7.43M(6.74%)